Malignant melanomas are aggressive tumors that are largely refractory to conventional drug therapies. A recent study reported in Nature Genetics identified mutationally activated ErbB4 alleles in 20% of cases. These tumor cells exhibit ErbB4 dependency, suggesting that ErbB4 kinase inhibition may constitute an effective therapeutic strategy in this setting. © 2009 Elsevier Inc. All rights reserved.
Settleman, J. (2009, October 6). A Therapeutic Opportunity in Melanoma: ErbB4 Makes a Mark on Skin. Cancer Cell. https://doi.org/10.1016/j.ccr.2009.09.013